TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02627534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonic debridement
Description: All periodontal pockets received ultrasonic debridement (Cavitron, Dentsply) with specific inserts (UI25KSF10S, Hu-Friedy). All diseased sites were instrumented in one session by an experienced periodontist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic debridement
Description: All periodontal pockets received ultrasonic debridement (Cavitron, Dentsply) with specific inserts (UI25KSF10S, Hu-Friedy). All diseased sites were instrumented in one session by an experienced periodontist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy
Description: After ultrasonic debridement, one randomly selected periodontal pocket received an additional aPDT performed by a trained operator (NMRBA). One pocket with probing depth ≥ 5mm in each patient was randomly selected to aPDT. After washing the pocket with saline solution, the photosensitizer (methylene blue 10mg/ml) was applied to the bottom of the pocket in a coronal direction. Following this, the pocket was exposed to a diode laser light with a fibre optic application for 1 min (Thera Lase DMC - Brazil), with wavelength of 660nm, power of 60mW and fluency of 129J/cm2.
Study: NCT02551003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous cord blood
Description: Autologous cord blood will be collected after birth and administered in divided aliquots during the first 3 days of life. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermia
Description: Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
Study: NCT03065283

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragm lift
Description: The purpose is to generate the stretch of the peripheral fibers of the diaphragm, being performed with the patient in the supine position and the physiotherapist standing on the patient's head and Pulling the Your costal arch In the cephalic direction, for one minute, twice
Study: NCT02586961

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline solution
Description: Placebo:~Nebulized 0.9% saline solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral betamethasone placebo
Description: placebo of oral betamethasone: equivalent of 1 mg/kg at inclusion followed by five once-daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenaline
Description: Catecholamine nebulized adrenaline (3 ml of 1:1000 solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral betamethasone
Description: Mineralocorticoid: a short course of oral betamethasone: 1.0 mg/kg at inclusion, followed by five once-daily doses (0.6 mg/kg)
Study: NCT03065283

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Diaphragm lift
Description: The purpose is to generate the stretch of the peripheral fibers of the diaphragm, being performed with the patient in the supine position and the physiotherapist standing on the patient's head and Pulling the Your costal arch In the cephalic direction, for one minute, twice

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation of the diaphragm pillars
Description: Second technique aims to promote the rhythmic stretching of the double psoas diaphragm pillars, being performed with The patient in the ventral position and the therapist standing at his side placing the ulnar border of his cephalic hand on the last ribs and his caudal hand flattened in front of the popliteal fossa of the popliteal fossa, stretching was done for one minute

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Relaxation of the diaphragm pillars
Description: Second technique aims to promote the rhythmic stretching of the double psoas diaphragm pillars, being performed with The patient in the ventral position and the therapist standing at his side placing the ulnar border of his cephalic hand on the last ribs and his caudal hand flattened in front of the popliteal fossa of the popliteal fossa, stretching was done for one minute
Study: NCT04699643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVER4010001
Description: Please refer to information in arm/group descriptions.
Study: NCT00798785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-MMF-TAC
Description: ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant subcutaneous (total n=5) at the time of the first clinical implant in the liver.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-Rituximab-MMF-TAC
Description: ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Rituximab: the day before transplantation, day 5; 12 and 19 after implantation. Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-basilixumab-MMF-TAC
Description: First transplantation:~ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Second transplantation:~Basilixumab:~the day before the second transplantation followed by 4days after transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: omentum
Description: Two clinical implants: first in omentum followed by a clinical implant in the liver:~In a group of 10 patients, a clinical implant in the omentum will be implanted. If random C-peptide levels \>= 0.5 ng/ml are measured at 2 months post-transplantation, a second omental implant will be done. If no clinical relevant beta cell graft function is measured, two intraportal implants will be given as a compassionate use procedure. An interim analysis after 5 patients has to shown clinical relevant function at month 2 in 3 out of 5 patients before the subsequent 5 patients can be transplanted in the omentum.
Study: NCT02971865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT/CMT
Description: Cognitive Behavioral Therapy (CBT - training to change nutritional thoughts and behaviors) and Chiropractic Manipulative Therapy (CMT - High Velocity, low amplitude chiropractic manipulation) were delivered in average total 8 visits in a year. The interventions were comparable in format (individual visit), duration (30 minute visits), frequency (monthly), and number of participants per group (see intervention details). Each intervention was delivered according to a protocol in which all instructors were trained. (Figure 3: Chiropractic/Behavioral health and Primary care Integration Protocol.) Routine care varied with patient complaints at the time of visit.
Study: NCT03841227

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active-tDCS
Description: Active home-based tDCS applied at home. 5 days a week for 4 weeks.
Study: NCT02971865

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group traditional primary care
Description: No change in care usually given
Study: NCT02028702

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water with color

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red Clover extract
Description: Red Clover extract containing 80 mg Isoflavones. Dosage: 2 X 75 ml/day
Study: NCT02581761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYTOTEC
Description: synthetic prostaglandin E1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active material
Study: NCT01503359

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sarcosine
Description: Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months.~Placebo group patients will receive 2 grams of placebo once a day in the morning for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sarcosine
Description: Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months.~Placebo group patients will receive 2 grams of placebo once a day in the morning for 6 months.
Study: NCT02170129

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 50% AAB plus 50% autologous bone
Description: All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later.~Both groups received tapered implants with an anodised surface.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 100% AAB
Description: All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later. Both groups received tapered implants with an anodised surface.
Study: NCT02836340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-Iminobiotin
Description: The Investigational Medicinal Product (IMP) under study is 2-IB, which is a biotin (Vitamin H or B7) analogue and a selective inhibitor of neuronal and inducible nitric oxide synthase (NOS).
Study: NCT02680977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MP-Equivalent
Description: Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MP-Low
Description: Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MP+DDCI
Description: Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI. Benserazide is given as 1:4 ratio with Levodopa.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LD+DDCI
Description: Levodopa plus Benserazide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LD-DDCI
Description: Levodopa without any DDCI

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Groundnuts powder
Study: NCT04613895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
Study: NCT04551352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7293583
Description: RO7293583 will be administered at a dose and per schedule as specified for the respective cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7293583
Description: RO7293583 will be administered at a dose and per schedule as specified for the respective cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as required for the management of severe cytokine release syndrome (CRS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as required for the management of severe cytokine release syndrome (CRS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: If implemented, it will be given either on D-7 or D-7 and D-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: If implemented, it will be given as a single dose approximately 6 days prior to the first dose of RO7293583.
Study: NCT02196506

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + ADT
Description: Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
Study: NCT01950468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAV5001
Description: A single intravenous dose of 8.0 ± 1.0 mCi

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DaTscan
Description: A single intravenous dose of 3 to 5 mCi
Study: NCT00984542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Bendamustine 120 mg/m2 IV on days 1 and 2 of a 21-day treatment cycle
Study: NCT04093310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Word Catheter
Description: Use of the Word catheter to remove the Bartholin's abscess

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision-drainage
Description: Incision-drainage to remove the Bartholin's abscess
Study: NCT03105362

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enterade® oral rehydration solution
Description: Commercially available amino acid based oral rehydration solution
Study: NCT02196506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole +ADT
Description: Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)
Study: NCT00846196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risedronate DR (Phase III clinical supply)
Description: Reference - (Phase III clinical supply) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate 35 mg DR (Commercial Tablet)
Description: Test - (Commercial tablets) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
Study: NCT03816800

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ImmunoBon
Description: The dietary agent contains vitamin A, Zn, chelated iron and whey proteins.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the dietary agent does not contain vitamin A, Zn, chelated iron and whey proteins
Study: NCT04130945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: erector spina plane block, cost analysis
Description: in preopererative period, ESP block is going to utilise for postoperative analgesia for patients who undergo laparoscopic procedure and cost analysis will make after the end of 24 hour of operation
Study: NCT04036448

Intervention type: DRUG
Intervention: REVLIMID®
Description: REVLIMID®

Intervention type: DRUG
Intervention: REVLIMID®
Description: REVLIMID®
Study: NCT01925430

Intervention type: DEVICE
Intervention: Screening device
Description: Non-invasive device worn over clothes during sleep. Used to screen for sleep-disordered breathing conditions.

Intervention type: DEVICE
Intervention: Comparative product
Description: A non-invasive device worn on the arm or leg. It monitors body movement and sleep/wake states
Study: NCT03152877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Liposome Injectable Product
Description: 20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% plain bupivacaine
Description: 20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
Study: NCT01616797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized neurobehavioral intervention
Description: Participants will complete the intervention by logging into a secure online website and complete computerized neurobehavioral tasks. Tasks will train the following - cognitive control, working memory and task shifting with two different tasks that engage these skills and positivity biases.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computerized neurobehavioral intervention
Description: Participants will complete the intervention by logging into a secure online website and complete computerized neurobehavioral tasks. Tasks will train the following - cognitive control, working memory and task shifting with two different tasks that engage these skills and positivity biases.
Study: NCT00913263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-hydroxyflutamide (2-HOF) [Liproca Depot]
Description: Ready made paste including 600 mg 2-HOF for injection as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-Hydroxyflutamide
Description: The Product consists of two sterile components, one aqueous liquid and a dry powder, containing the active drug 2-Hydroxyflutamide (2-HOF. The two components were mixed under aceptic conditions to a paste prior to administration.
Study: NCT00313196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: Oral Initial dose: 62.5 mg b.i.d. for 4 weeks for all patients, maintenance dose: 125 mg
Study: NCT02790099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Surgical rectus sheath block will be performed by injection of 40ml bupivacaine (2.5mg/ml) before closure of rectus sheath during the operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Surgical rectus sheath block will be performed by injection of 40ml bupivacaine (2.5mg/ml) before closure of rectus sheath during the operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.1mg preservative free morphine will be injected intrathecally by anaesthesiologist at the time of spinal anaesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.1mg preservative free morphine will be injected intrathecally by anaesthesiologist at the time of spinal anaesthesia.
Study: NCT01400490

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA-DHA Study
Description: 6 weeks of dietary supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA-DHA Study
Description: 6 weeks of dietary supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA-DHA Study
Description: 6 weeks of dietary supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EPA-DHA Study
Description: 6 weeks of dietary supplementation
Study: NCT01554670

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RF micro-tenotomy
Description: an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
Study: NCT02522884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tack Endovascular System
Description: Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
Study: NCT04014205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib (ICP-022)
Description: ICP-022 The drug product is a white, round, uncoated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib (ICP-022)
Description: ICP-022 The drug product is a white, round, uncoated tablet
Study: NCT00715273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 10 to 80 mg of atorvastatin each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 10 to 80 mg of atorvastatin each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 10 to 80 mg of atorvastatin each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: 2000 mg of niacin each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: 2000 mg of niacin each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: 3.8 g of colesevelam each day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Niacin
Description: Placebo niacin each day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Colesevelam
Description: Placebo colesevelam each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Colesevelam
Description: Placebo colesevelam each day